TEVA PHARMACEUTICAL-SP ADR(NYSE:TEVA) stock News

TEVA Latest News, Press Relases and Analysis

All

Press Releases

3 hours ago - By: Zacks Investment Research - Mentions: JNJ AMGN KVUE

J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?

4 days ago - By: Benzinga - Mentions: ISRG LLY MDT NVO ...

10 Health Care Stocks With Whale Alerts In Today's Session

4 days ago - By: Zacks Investment Research - Mentions: JNJ AMGN

Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?

5 days ago - By: The Motley Fool - Mentions: PLTR NVDA

Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters

7 days ago - By: Benzinga

How Is The Market Feeling About Teva Pharmaceutical Indus?

a month ago - By: Investor's Business Daily

Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings

19 days ago - By: Teva Pharmaceutical Industries Ltd

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

26 days ago - By: Yahoo Finance

Teva Reaffirms 2025 Sales, Boosts Outlook For Austedo, Ajovy, Uzedy

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

a month ago - By: Teva Pharmaceutical Industries Ltd

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

a month ago - By: The Motley Fool - Mentions: PLTR TSM

Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters

a month ago - By: Zacks Investment Research - Mentions: JNJ AMGN KVUE

JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise

2 months ago - By: Yahoo Finance

Teva’s Ajovy Shows Sustained Long-Term Efficacy in Migraine Prevention Trial

2 months ago - By: Teva Pharmaceutical Industries Ltd

Teva Releases Q2 2025 Aide Memoire

2 months ago - By: Teva Pharmaceutical Industries Ltd

Teva Releases Q2 2025 Aide Memoire

2 months ago - By: Yahoo Finance - Mentions: VZ

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

2 months ago - By: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

2 months ago - By: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

2 months ago - By: Teva Pharmaceutical Industries Ltd

Les données définitives de l’étude PEARL menée par Teva en conditions réelles confirment l’efficacité à long terme d’AJOVY® (frémanézumab) pour la prévention de la migraine chronique et épisodique

2 months ago - By: Teva Pharmaceutical Industries Ltd

Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit von AJOVY® (fremanezumab) für die Prävention chronischer und episodischer Migräne

2 months ago - By: Teva Pharmaceutical Industries Ltd

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

2 months ago - By: FN Media Group LLC - Mentions: EBS PFE NTRB COLL

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

2 months ago - By: Yahoo Finance - Mentions: ORCL NVDA AMZN MSFT ...

Prediction: This Artificial Intelligence (AI) Stock Will Lead the Next Tech Bull Market

2 months ago - By: Teva Pharmaceutical Industries Ltd

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

2 months ago - By: Yahoo Finance - Mentions: O PLTR AMZN V ...

This Stock Pays a Monthly Dividend and Is Up 4x More Than the S&P 500. Is It a Buy?

3 months ago - By: Zacks Investment Research - Mentions: VTRS

TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock News

TEVA Latest News, Press Relases and Analysis

J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?

10 Health Care Stocks With Whale Alerts In Today's Session

Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?

Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters

How Is The Market Feeling About Teva Pharmaceutical Indus?

Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Teva Reaffirms 2025 Sales, Boosts Outlook For Austedo, Ajovy, Uzedy

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters

JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise

Teva’s Ajovy Shows Sustained Long-Term Efficacy in Migraine Prevention Trial

Teva Releases Q2 2025 Aide Memoire

Teva Releases Q2 2025 Aide Memoire

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Les données définitives de l’étude PEARL menée par Teva en conditions réelles confirment l’efficacité à long terme d’AJOVY® (frémanézumab) pour la prévention de la migraine chronique et épisodique

Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit von AJOVY® (fremanezumab) für die Prävention chronischer und episodischer Migräne

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

Prediction: This Artificial Intelligence (AI) Stock Will Lead the Next Tech Bull Market

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

This Stock Pays a Monthly Dividend and Is Up 4x More Than the S&P 500. Is It a Buy?

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats